Edaravone prevents neurotoxicity of mutant L166P DJ-1 in Parkinson's disease

Journal of Molecular Neuroscience

Volumn 51, Issue 2, 2013, Pages 539-549

  Li, Bing ^a   Yu, Dawei ^b   Xu, Zhiying ^b  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b YANTAISHAN HOSPITAL   (China)

Author keywords

Apoptosis; Edaravone; Mitochondrial dysfunction; Oxidative stress; Parkinson's disease

Indexed keywords

ADENOSINE TRIPHOSPHATE; DJ 1 PROTEIN; NEUROPROTECTIVE AGENT; NORPHENAZONE; PROTEIN; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FAMILIAL DISEASE; GENE OVEREXPRESSION; IN VITRO STUDY; LOSS OF FUNCTION MUTATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NEUROMODULATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; UPREGULATION;

ANIMALS; ANTIPYRINE; APOPTOSIS; CELL LINE, TUMOR; FREE RADICAL SCAVENGERS; MICE; MITOCHONDRIA; MUTATION; ONCOGENE PROTEINS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84885178135     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-013-0022-8     Document Type: Article

References (45)

1. Amemiya S, Kamiya T, Nito C, Inaba T, Kato K, Ueda M, Shimazaki K, Katayama Y (2005) Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. Eur J Pharmacol 516:125-130
2. Bonifati V, Rizzu P, van Baren MJ et al (2003a) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256-259
3. Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC, Brice A, van Duijn CM, Oostra B, Meco G et al (2003b) DJ-1 (PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 24:159-160
4. Canet-Avilés RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, Cookson MR (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A 101:9103-9108
5. Chen H, Wang S, Ding JH, Hu G (2008) Edaravone protects against MPP+-induced cytotoxicity in rat primary cultured astrocytes via inhibition of mitochondrial apoptotic pathway. J Neurochem 106(6):2345-2352
6. Cookson MR (2012) Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways. Cold Spring Harb Perspect Med 2(9):a009415
7. Crosiers D, Theuns J, Cras P, Van Broeckhoven C (2011) Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. J Chem Neuroanat 42(2):131-141
8. Deeg S, Gralle M, Sroka K, Bahr M, Wouters FS, Kermer P (2010a) BAG1 restores formation of functional DJ-1 L166P dimers and DJ-1 chaperone activity. J Cell Biol 188:505-513
9. Deeg S, Gralle M, Sroka K, Bahr M, Wouters FS, Kermer P (2010b) BAG1 restores formation of functional DJ-1 L166P dimers and DJ-1 chaperone activity. J Cell Biol 188:505-513
10. Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med [Epub ahead of print]
11. Edaravone Acute Infarction Study G (2003) Effect of a novel free radical scavenger, edaravone (mci-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15:222-229
12. Fan J, Ren H, Jia N, Fei E, Zhou T, Jiang P, Wu M, Wang G (2008) DJ-1 decreases Bax expression through repressing p53 transcriptional activity. J Biol Chem 283:4022-4030
13. Giaime E, Sunyach C, Druon C et al (2010) Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6. Cell Death Differ 17:158-169
14. Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B (2006) Gain-offunction haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet 15:299-305
15. Goldberg MS, Pisani A, Haburcak M et al (2005) Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45:489-496
16. Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S et al (2008) Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 213:448-455
17. Itoh T, Satou T, Nishida S, Tsubaki M, Hashimoto S et al (2009) The novel free radical scavenger, edaravone, increases neural stem cell number around the area of damage following rat traumatic brain injury. Neurotox Res 16:378-389
18. Kawai H, Nakai H, Suga M, Yuki S, Watanabe T, Saito KI (1997) Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 281(2):921-927
19. Kawasaki T, Ishihara K, Ago Y, Nakamura S, Itoh S, Baba A, Matsuda T (2006) Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Eur J Pharmacol 542:92-99
20. Kawasaki T, Ishihara K, Ago Y, Baba A, Matsuda T (2007) Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum. J Pharmacol Exp Ther 322(1):274-281
21. Kim RH, Smith PD, Aleyasin H et al (2005) Hypersensitivity of DJ-1-deficient mice to 1-mthyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and oxidative stress. Proc Natl Acad Aci U S A 102:5215-5220
22. Lang AE, Lozano AM (1998) Parkinson's disease. First of two parts. N Engl J Med 339:1044-1053
23. Lees AJ, Hardy J, Revesz T (2009) Parkinson's disease. Lancet 373:2055-2066
24. Lin Z, Zhao Y, Chung CY, Zhou Y, Xiong N, et al. (2010) High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life. FASEB J 24:2191-2200
25. Meulener M, Whitworth AJ, Armstrong-Gold CE, Rizzu P, Heutink P, Wes PD, Pallanck LJ, Bonini NM (2005) Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr Biol 15:1572-1577
26. Mo JS, Kim MY, Ann EJ, Hong JA, Park HS (2008) DJ-1 modulates UV-induced oxidative stress signaling through the suppression of MEKK1 and cell death. Cell Death Differ 15:1030-1041
27. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28:57-87
28. Nakamura T, Kuroda Y, Yamashita S, Zhang X, Miyamoto O et al (2008) Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke 39:463-469
29. Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK et al (2010) In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med 51:223-228
30. Rajesh KG, Sasaguri S, Suzuki R, Maeda H (2003) Antioxidant MCI-186 inhibits mitochondrial permeability transition pore and upregulates Bcl-2 expression. Am J Physiol Heart Circ Physiol 285:H2171-H2178
31. Ren H, Fu K, Mu C, Zhen X, Wang G (2012) L166P mutant DJ-1 promotes cell death by dissociating Bax from mitochondrial Bcl-XL. Mol Neurodegener 7:40
32. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P (2004) Vandenabeele toxic proteins released from mitochondria in cell death. Oncogene 23:2861-2874
33. Sharma P, Sinha M, Shukla R, Garg RK, Verma R, Singh MK (2011) A randomized controlled clinical trial to compare the safety and efficacy of edaravone in acute ischemic stroke. Ann Indian Acad Neurol 14(2):103-106
34. Sheng B, Gong K, Niu Y, Liu L, Yan Y, Lu G, Zhang L, Hu M, Zhao N, Zhang X, Tang P, Gong Y (2009) Inhibition of gamma-secretase activity reduces Abeta production, reduces oxidative stress, increases mitochondrial activity and leads to reduced vulnerability to apoptosis: implications for the treatment of Alzheimer's disease. Free Radic Biol Med 46(10):1362-1375
35. Sheng B, Wang X, Su B, Lee HG, Casadesus G, Perry G, Zhu X (2012) Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J Neurochem 120(3):419-429
36. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H (2004) DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 5:213-218
37. Tsujita K, Shimomura H, Kawano H, Hokamaki J, Fukuda M, Yamashita T, Hida S, Nakamura Y, Nagayoshi Y, Sakamoto T, Yoshimura M, Arai H, Ogawa H (2004) Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am J Cardiol 94:481-484
38. Tsujita K, Shimomura H, Kaikita K, Kawano H, Hokamaki J, Nagayoshi Y, Yamashita T, Fukuda M, Nakamura Y, Sakamoto T, Yoshimura M, Ogawa H (2006) Long-term efficacy of edaravone in patients with acute myocardial infarction. Circ J 70:832-837
39. Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S (2001) Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 98:2837-2842
40. Xiong N, Xiong J, Khare G, Chen C, Huang J, Zhao Y, Zhang Z, Qiao X, Feng Y, Reesaul H, Zhang Y, Sun S, Lin Z, Wang T (2011a) Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease. PLoS One 6(6):e20677
41. Xiong N, Xiong J, Khare G, Chen C, Huang J, Zhao Y, Zhang Z, Qiao X, Feng Y, Reesaul H, Zhang Y, Sun S, Lin Z, Wang T (2011b) Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease. PLoS One 6(6):e20677
42. Yan Y, Gong K, Ma T, Zhang L, Zhao N, Zhang X, Tang P, Gong Y (2012) Protective effect of edaravone against Alzheimer's disease-relevant insults in neuroblastoma N2a cells. Neurosci Lett 531(2):160-165
43. Ying HS, Gottron FJ, Choi DW (2001) Assessment of cell viability in primary neuronal cultures. Curr Protoc Neurosci Chapter 7:Unit 7.18. doi: 10.1002/0471142301.ns0718s13
44. Yuan WJ, Yasuhara T, Shingo T, Muraoka K, Agari T et al (2008a) Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neurosci 9:75
45. Yuan WJ, Yasuhara T, Shingo T et al (2008b) Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neurosci 9:75